BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
1928 results:

  • 1. Biogenic Zinc Oxide Nanoparticles synthesized from
    Berehu HM; Patnaik S
    Nanotheranostics; 2024; 8(3):312-329. PubMed ID: 38577319
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
    Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
    Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.
    Li H; Feng H; Zhang T; Wu J; Shen X; Xu S; Xu L; Wang S; Zhang Y; Jia W; Ji X; Cheng X; Zhao R
    Mol Cancer; 2024 Mar; 23(1):59. PubMed ID: 38515149
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
    Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
    Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Differential genetic mutations and immune cell infiltration in high- and low-risk STAD: Implications for prognosis and immunotherapy efficacy.
    Deng YY; Sun Y; Wu SJ; Zhang TY; Yang J; Liu K
    J Cell Mol Med; 2024 Apr; 28(7):e18174. PubMed ID: 38494839
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Evaluating the role of wound-healing genes in conjunction with stool routine and serum tumor markers for colorectal cancer diagnosis and prognostic implications.
    Yu K; Fang X
    Int Wound J; 2024 Mar; 21(3):e14768. PubMed ID: 38446012
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells.
    Kakafika MG; Lyta AA; Gavriilidis GI; Tsiftsoglou SA; Miliotou AN; Pappas IS; Vizirianakis IS; Papadopoulou LC; Tsiftsoglou AS
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426621
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Morindone as a potential therapeutic compound targeting tp53 and KRAS mutations in colorectal cancer cells.
    Chee CW; Mohd Hashim N; Nor Rashid N
    Chem Biol Interact; 2024 Apr; 392():110928. PubMed ID: 38423379
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
    Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
    Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
    Alruwaili MM; Zonneville J; Naranjo MN; Serio H; Melendy T; Straubinger RM; Gillard B; Foster BA; Rajan P; Attwood K; Chatley S; Iyer R; Fountzilas C; Bakin AV
    Cell Rep Med; 2024 Mar; 5(3):101434. PubMed ID: 38387463
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Induction of G0/G1 phase cell cycle arrest and apoptosis by thymol through ROS generation and caspase-9/-3 activation in breast and colorectal cancer cell lines.
    Anvarbatcha R; Kunnathodi F; Islam M
    J Cancer Res Ther; 2023 Oct; 19(7):1915-1924. PubMed ID: 38376297
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Villosol reverses 5-FU resistance in colorectal cancer by inhibiting the CDKN2A gene regulated tp53-PI3K/Akt signaling axis.
    Chen H; Deng J; Hou TW; Shan YQ
    J Ethnopharmacol; 2024 May; 325():117907. PubMed ID: 38342156
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study.
    Alalikhan A; Ebrahimi S; Aliee A; Mirzavi F; Hashemy SI
    Med Oncol; 2024 Feb; 41(3):70. PubMed ID: 38340190
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
    Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
    J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Development and Nanoparticle-Mediated Delivery of Novel MDM2/MDM4 Heterodimer Peptide Inhibitors to Enhance 5-Fluorouracil Nucleolar Stress in colorectal cancer Cells.
    Merlino F; Pecoraro A; Longobardi G; Donati G; Di Leva FS; Brignola C; Piccarducci R; Daniele S; Martini C; Marinelli L; Russo G; Quaglia F; Conte C; Russo A; La Pietra V
    J Med Chem; 2024 Feb; 67(3):1812-1824. PubMed ID: 38285632
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Inhibition of Autophagy Aggravates
    Tsai CH; Huang HC; Lin KJ; Liu JM; Chen GL; Yeh YH; Lu TL; Lin HW; Lu MT; Chu PC
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279345
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Beetroot extract@chitosan nanocomposite as a promising approach towards cancer therapy.
    El-Ghannam G; Moawad M; Abo-Elfadl MT; Elfeky SA
    Int J Biol Macromol; 2024 Mar; 261(Pt 1):129700. PubMed ID: 38278395
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
    Chiba Y; Kagabu M; Osakabe M; Ito R; Sato S; Takatori E; Kaido Y; Nagasawa T; Shoji T; Yanagawa N; Baba T
    Jpn J Clin Oncol; 2024 Apr; 54(4):424-433. PubMed ID: 38251744
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 97.